Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boehringer-Ingelheim Now RE-LYing On Pradaxa Approval In Stroke Prevention

Executive Summary

As Boehringer-Ingelheim scrambles to file its oral anticoagulant Pradaxa with FDA, likely for stroke prevention in patients with atrial fibrillation, physicians already have started weighing the pros and cons of the drug's two possible doses

You may also be interested in...



FDA Supports Pradaxa Approval, But Without Superiority Claim

Agency charges the Sept. 20 Cardiovascular and Renal Drugs Advisory Committee with evaluating the relative benefit of preventing strokes with the increased risk of bleeding posed by Boehringer Ingelheim's dabigatran.

Heart Attack Signal Is Likely Focus For Panel Review Of Boehringer Ingelheim's Pradaxa

When FDA's Cardiovascular and Renal Drugs Advisory Committee meets Sept. 20 to consider Boehringer Ingelheim's Pradaxa (dabigatran) for stroke prevention, a significantly higher rate of heart attacks among clinical trial patients compared with warfarin is likely to come up.

Momentum Grows For Novel Oral Anticoagulants Out To Replace Warfarin

The attributes of Merck/Portola's Factor Xa inhibitor betrixaban, and where it fits in the crowded development space of novel anticoagulants, came into sharper focus with the release of new Phase II data at the American College of Cardiology annual meeting

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel